Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

NCT04080635

Status	RECRUITING
Phase	Not Applicable
Sponsor	University Hospital, Ghent
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (2)

- Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis
- Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion (4)

- Participants who have currently a predominant nonplaque form of psoriasis
- Participants who are pregnant, nursing or planning a pregnancy
- Participants who are unable or unwilling to undergo multiple venapunctures
- Participants who are treated according to a different dosing schedule than standard dosing of brodalumab

Locations (7 total)

AZ Maria Middelares, Ghent, Oost-Vlaanderen, Belgium
AZ Sint-Lucas, Ghent, Oost-Vlaanderen, Belgium
University Hospital of Ghent, Ghent, Oost-Vlaanderen, Belgium
... and 4 more locations